“Travel and tourism builds diversified and resilient economies”: Saudi Arabia Minister of Tourism, His Excellency Ahmed Al-Khateeb, tells World Economic Forum Annual Meeting in Davos
24.1.2025 20:59:00 CET | Business Wire | Press release
Official Travel & Tourism sessions were prominently featured on the WEF agenda, with global leaders unpacking the transformative power of the sector. His Excellency urged global leaders to give the sector the attention it deserves to catalyze sustainable, cross-border, multi-sector economic growth.
The Travel and Tourism sector’s essential contribution to shaping the global landscape was underscored at the World Economic Forum (WEF) Annual Meeting in Davos this week with His Excellency Ahmed A. Al-Khateeb, Saudi Arabia Minister of Tourism, urging world leaders to provide the industry with the focus and collaborative solutions it deserves.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250124536028/en/
Saudi Minister of Tourism, His Excellency Ahmed A. Al-Khateeb put travel and tourism on the global agenda at the World Economic Forum Annual Meeting in Davos, Switzerland, this week. (Photo: AETOSWire)
Saudi Arabia welcomed nearly 30 million international visitors in 2024 and contributed almost 5% to the Kingdom’s GDP. In dedicated WEF sessions on travel and tourism, His Excellency, who attended Davos as part of the official Saudi Arabia WEF Delegation, highlighted the Kingdom’s unprecedented growth rates. He stressed the critical role that tourism has in building diversified and resilient economies, emphasizing that when Saudi Vision 2030 unlocked the travel and tourism sector, the Kingdom began building a holistic tourism experience based on international collaboration, best practices, and sustainable development.
As the WEF Annual Meeting concluded, His Excellency noted that the world was watching the remarkable resurgence of tourism, with the industry now fully recovered to pre-pandemic levels with 1.4 billion international arrivals in 2024.
“The world is counting on us to build a vibrant tourism ecosystem that meets growing demand while safeguarding our planet and quality of life. Tourism is more than an industry - it is a transformative force. We need to foster collective action to balance economic growth in the industry with social and environmental responsibility and ensuring the sector's resilience,” His Excellency said.
Throughout the forum, His Excellency led discussions as a key voice on official WEF panels including "Travel and Tourism’s Role in Building Trust” and "The Way We Will Travel”, focused on mobilizing diversified sector growth and enhancing global collaboration to propel the travel and tourism sector to keep up with growing demand, as well as a high-level session at Saudi House that explored “Scaling Sustainable Tourism: Connecting People and Places.”
He shared the stage with distinguished leaders, including Albania Prime Minister Edi Rama, European Commissioner for Transport and Tourism Apostolos Tzitzikostas, Switzerland Tourism CEO Martin Nydegger and Trip.com CEO Jane Sun who all shared His Excellency’s sentiment on the need for further global collaboration.
In alignment with Saudi Arabia’s forward-thinking tourism strategy, the Ministry launched a new investment guide, the "Hospitality Investor White Paper" during the WEF Annual Meeting. This initiative supports Vision 2030's ambitious targets, aiming to attract more than SAR 40 billion (USD 11 billion) in private investments, contribute SAR 16 billion (USD 4 billion) to the GDP, and create 1.6 million jobs by 2030.
Minister Al-Khateeb also contributed expert insights to the WEF’s "The Future of Travel and Tourism: Embracing Sustainable and Inclusive Growth” briefing paper highlighting the growing demand for sustainable travel and the importance of cross-sector collaboration and the need to ensure local communities globally benefit from the resulting growth.
As the WEF Annual Meeting concludes, Minister Al-Khateeb's participation underscores Saudi Arabia's transformative role in reshaping the global tourism landscape, reinforcing the Kingdom's vision to establish itself as a leading hub for sustainable travel.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250124536028/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom